Colleen Kusy
Stock Analyst at Baird
(1.65)
# 3,134
Out of 4,732 analysts
40
Total ratings
24.32%
Success rate
-6.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CHRS Coherus BioSciences | Maintains: Outperform | $4 → $6 | $1.39 | +331.65% | 5 | Dec 5, 2024 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $32 → $40 | $21.47 | +86.31% | 2 | Nov 15, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $20.62 | +215.23% | 2 | Nov 13, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $92 → $55 | $29.94 | +83.73% | 10 | Nov 7, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $0.62 | +384.97% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $8.01 | +112.23% | 4 | Aug 8, 2024 | |
| OCS Oculis Holding AG | Maintains: Outperform | $35 → $37 | $22.74 | +62.71% | 3 | Jun 11, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $9.58 | +160.96% | 1 | Mar 12, 2024 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $75.84 | +38.45% | 1 | Feb 23, 2024 | |
| AGEN Agenus | Initiates: Outperform | $160 | $3.48 | +4,497.70% | 1 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $0.66 | +2,020.89% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $5.91 | +475.30% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.53 | +6,415.58% | 1 | Nov 2, 2021 |
Coherus BioSciences
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.39
Upside: +331.65%
Enliven Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $32 → $40
Current: $21.47
Upside: +86.31%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $20.62
Upside: +215.23%
Apellis Pharmaceuticals
Nov 7, 2024
Maintains: Outperform
Price Target: $92 → $55
Current: $29.94
Upside: +83.73%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.62
Upside: +384.97%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $8.01
Upside: +112.23%
Oculis Holding AG
Jun 11, 2024
Maintains: Outperform
Price Target: $35 → $37
Current: $22.74
Upside: +62.71%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $9.58
Upside: +160.96%
Nuvalent
Feb 23, 2024
Initiates: Outperform
Price Target: $105
Current: $75.84
Upside: +38.45%
Agenus
Jun 6, 2023
Initiates: Outperform
Price Target: $160
Current: $3.48
Upside: +4,497.70%
Aug 5, 2022
Maintains: Outperform
Price Target: $17 → $14
Current: $0.66
Upside: +2,020.89%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $5.91
Upside: +475.30%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.53
Upside: +6,415.58%